Keywords: b-ms, licenses, ns2214, anti-parkinson, drug, bristol-myers, squibb

B-MS's licenses NS2214 anti-Parkinson's drug

Article | 22 January 1996

Print This

- Bristol-Myers Squibb has licensed marketing rights to NS2214, an oral drug for Parkinson's disease developed by NeuroSearch A/S of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in